Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

A course of Merck’s COVID-19 pill could cost more than $700

By Brian Buntz | October 7, 2021

Merck logoMerck’s (NYSE:MRK) oral drug molnupiravir (MK-4482) could be a COVID-19 game-changer, assuming it wins emergency use authorization.

The medicine could also be lucrative for Merck, assuming it finds widespread use.

Costing $712 for a treatment course, according to a contract obtained by Knowledge Ecology International, molnupiravir’s retail cost would be almost 40 times more than its production cost. It takes about $17.74 to produce a five-day course of the drug, according to an estimate from a pricing analysis from the Harvard School of Public Health and King’s College Hospital in London.

Knowledge Ecology International obtained the contract via a Freedom of Information Act lawsuit targeting the HHS and the Army regarding U.S. government COVID-19 contracts.

Merck did not immediately respond to a request for comment on its pricing plans related to the drug.

In initial contracts with the U.S., the Pfizer-BioNTech vaccine has a price tag of $19.50 per dose, while the Moderna’s costs about $15 per dose and Janssen’s around $10.

Despite the pandemic pricing, COVID-19 vaccines have been lucrative for Pfizer and Moderna.

Pfizer has stated in an earnings statement that the profit margin on the Pfizer-BioNTech COVID-19 vaccine is in the high twenty-percent range. The company expects 2021 revenues for the vaccine to hit $33.5 billion.

Moderna expects product sales to exceed $20 billion. The firm SOMO estimated that the profit margin on the Moderna vaccine is 44%.

Molnapiravir’s roots trace back to 2013, when researchers considered its potential as an oral treatment for encephalitic New World alphavirus VEEV (Venezuelan equine encephalitis virus), according to Current Opinions in Virology.

Then known as EIDD-2801, the drug also appeared to be effective against influenza.

Researchers at Emory University first discovered the drug as part of its Drug Innovation Ventures at Emory (DRIVE) program. DRIVE members later hooked up with Ridgeback Biotherapeutics to test the drug in humans in the early days of the pandemic.

By mid-2020, Merck had announced it was working with Ridgeback to develop the drug.

A statement from June 2020 stressed that “Merck and Ridgeback are committed to ensure that any medicines developed for SARS-CoV-2 will be accessible and affordable globally.”


Filed Under: Infectious Disease
Tagged With: covid-19, EIDD-2801, Merck, MK-4482, Molnupiravir
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Pfizer
Pfizer shares positive top-line data from Phase 3 Study of pneumococcal vaccine
Vaccine
The most common monkeypox vaccine side effects
FDA logo
FDA grants emergency use authorization to Jynneos monkeypox vaccine to support ‘dose sparing’
JYNNEOS vaccine
Jynneos vaccine: The best weapon against monkeypox?

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50